Stides Vivimed gets USFDA approval for Albendazole Tablets
Capital MarketVivimed Labs announced that its 50:50 JV Strides Vivimed, Singapore has received approval for Albendazole Tablets USP 200mg from the united States Food & Drug Administration (USFDA). This is the second generic approval by USFDA for Albendazole Tablets.
Albendazole Tablets is a generic version of Albenza Tablets@ of Amneal pharmaceuticals, Inc. According to IQVIA MAT data, the US market for Albendazole Tablets USP 200 mg is approximately US$ 100 Mn.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
